Latest Regulation News

Page 12 of 166
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Premier Investments’ FY26 profit from continuing operations fell 10.3% as Smiggle sales weakened, while Peter Alexander delivered another record year. The retailer is entering FY27 with cleaner inventory, a stronger dividend and a costly UK retreat still to absorb.
Victor Sage
Victor Sage
23 Oct 2026
Kinetiko Energy has moved its Brakfontein project closer to production, adopting a Phase 1 development plan and advancing permitting and CNG engineering. The progress comes with only 1.54 quarters of funding available, leaving the company reliant on pending capital and project payments.
Maxwell Dee
Maxwell Dee
23 Oct 2026
The Takeovers Panel has declined to examine a challenge to Zenith Minerals’ handling of Aurenne’s proposed $5 million funding, removing one regulatory obstacle to Forrestania Resources’ recommended takeover. The Panel said there was no reasonable prospect of declaring unacceptable circumstances, but detailed reasons are still to come.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Objective Corporation delivered 9% revenue growth and a 5% lift in net profit for FY2026, but the loss of a long-running Defence agreement and a separate NHVR contract will pressure recurring revenue in the year ahead. Management expects adjusted EBITDA of at least $40 million in FY2027 as it keeps investing in AI, sales capacity and potential acquisitions.
Victor Sage
Victor Sage
23 Oct 2026
Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.
Ada Torres
Ada Torres
23 Oct 2026
MLG Oz delivered a stronger earnings year, with statutory NPAT rising 19.2% and underlying EBITDA margin expanding to 13.4%. The mining services group has resumed dividends while taking on higher fleet investment and debt ahead of FY2027.
Victor Sage
Victor Sage
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
EQT Holdings delivered strong growth from its continuing businesses in FY26, but a superannuation exit, litigation and takeover uncertainty left group profit and dividends lower. The company says discussions with BGH Capital and TPG Global remain open, while targeting completion of the superannuation exit by the end of 2027.
Claire Turing
Claire Turing
21 Oct 2026
Investor Centre is pursuing a restructuring and potential ASX reinstatement after Pulse Markets lost its financial services licence, while the group reported $35,000 in cash and $3.213 million of drawn debt at 30 September. The company says a new Lake Volta funding arrangement could support working capital, but the filing leaves important questions about the facility and the proposed recapitalisation unanswered.
Claire Turing
Claire Turing
21 Oct 2026
Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
Ada Torres
21 Oct 2026
PLS has priced US$700 million of senior unsecured notes at an 8.00% coupon, adding a substantial source of funding as the lithium producer prepares for further capital investment. The notes mature in 2032, with settlement expected on 23 October subject to customary conditions.
Maxwell Dee
Maxwell Dee
21 Oct 2026

Browse the archive

Full archive